http://wl28www163.webland.ch en Wed, 08 Feb 2012 04:02:58 +0100 Research and Markets (http://www.researchandmarkets.com/research/553ec0/orthopedic_devices) has announced the addition of the "Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability" report to their offering. http://wl28www163.webland.ch/index.php?id=357849 357849 Thu, 26 May 2011 00:00:00 +0200 Biotech in the New EU Member States: Policy Recommendations The study carried-out on the development status and capacity of healthcare biotechnology in the new EU Member States and candidate countries shows a much contrasted picture of biotechnology development in this region. Each country has a different economic development strategy and a unique history and capacity in the life-science and healthcare sector which determines its path to development. Based on these observations, it would be unsuitable to propose general recommendations in a sort of unique formula to build or develop a healthy healthcare biotechnology sector. Donwnload free 14 pages report at our Download Section. http://wl28www163.webland.ch/index.php?id=196608 196608 Mon, 28 Sep 2009 00:00:00 +0200 The Food and Drug Administration approved Arzerra, a leukemia treatment that will be marketed by GlaxoSmithKline PLC for patients who have failed to respond to other therapies.Arzerra was developed by U.K.-based Glaxo and Danish company Genmab A/S. http://wl28www163.webland.ch/index.php?id=196443 196443 Wed, 28 Oct 2009 00:00:00 +0100 The international regulatory affairs network - regulanet® - currently mainly operating in Europe is increasingly active globally. http://wl28www163.webland.ch/index.php?id=191010 191010 Mon, 26 Oct 2009 00:00:00 +0100 One of the first institutional network partners is the swiss national biotech industry association - Swiss Biotech Association. http://wl28www163.webland.ch/index.php?id=191357 191357 Fri, 23 Oct 2009 00:00:00 +0200 Biotech in the New EU Member States: an Emerging Sector This report is the first of its kind to try and understand the state of the biotechnology industry in the new Member States and candidate countries. As with any bottom-up work, it took a lot of effort and persistence to gather data on current and prospective developments in this area. Our goal was to strengthen the understanding of the European biotechnology scene and we believe that with the knowledge accumulated we have reached this goal. This report should enable policy makers and investors to make informed decisions about biotechnology support and development. The databases developed during this project will also provide better international visibility to the companies, which could lead to new cooperation or investment. Donwnload free 33 pages report at our Download Section. http://wl28www163.webland.ch/index.php?id=196622 196622 Mon, 28 Sep 2009 00:00:00 +0200 0 http://wl28www163.webland.ch/index.php?id=272362 272362 Thu, 01 Jan 1970 01:00:00 +0100 Lacerta BioCapital Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies. Please contact us for introduction to Lacerta BioCapital. http://wl28www163.webland.ch/index.php?id=282561 282561 Thu, 25 Feb 2010 12:06:56 +0100 Seeking: Novel new sensations and materials for lip products A kiss may be just a kiss, but we're looking for unique materials to add to lip products for new lip sensations and experiences (such as cooling, warming, numbing, tingling and flavors), solutions that can impart prolonged sensate experiences, and solutions that can impart not-yet-known sensations. http://wl28www163.webland.ch/index.php?id=275063 275063 Mon, 11 Jan 2010 21:59:54 +0100 Development-stage pain products The Company seeks to divest its development-stage pain products MGX-001 (extended release morphine combined with an atypical stimulant) and MGX-002 (a follow-on opioid combined with an atypical stimulant). These products are expected to significantly reduce commonly-experienced side effects versus existing opiate therapies. http://wl28www163.webland.ch/index.php?id=275077 275077 Tue, 15 Dec 2009 23:21:58 +0100 Bacteria strains and fermentation technologies Farmavita.Net member is seeking bacteria strains and fermentation technologies to produce the following products Lycopene, Chlortetracycline and Acetylisovaleryltylosin. http://wl28www163.webland.ch/index.php?id=275091 275091 Fri, 11 Dec 2009 13:12:33 +0100 Mapping the Healthcare Landscape: Bringing pharmaceuticals into focus Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration. Claim 10% Discount for Farmavita.Net Members when purchasing this report! http://wl28www163.webland.ch/index.php?id=275105 275105 Thu, 03 Dec 2009 09:51:58 +0100